- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00874809
Diabetes Mellitus Type 2 Basal Insulin Dosing Requirements Study
August 23, 2013 updated by: Allen B. King, MD, Diabetes Care Center
A Pilot Study to Explore Basal Insulin Dosing Requirements in Patients With Type 2 Diabetes Treated With Insulin Pump Therapy
The main purpose of this study is to determine the number of daily basal insulin rate changes that are needed to achieve short-term near normal glucose control in insulin pump patients with type 2 diabetes
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Subjects will be taught CHO counting after which they will be introduced to an insulin pump.
They will wear the insulin pump for three weeks to adjust to the pump and its functions.
Then the subject will wear a Continuous Glucose Monitoring System to determine rate changes needed to achieve short-term near normal glucose control.
The primary endpoint is what are the mean number of changes in the basal infusion rate and what are the mean differences and mean duration of these changes.
The secondary endpoint is what mathematical formulas describe the relationship between the dosing factors and do they significantly differ from those previously established by King and Armstrong.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Salinas, California, United States, 93901
- Diabetes Care Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Type 2 diabetes > 3month duration
- Age 18
- Hb A1C <12%
- On any hypoglycemic therapy including insulin for 5 patients and 5 patients naive to insulin and failing oral treatment
- Normal creatine
- Negative for GAD antibodies
- SMBG >4/d and willing/able to comply with study requirements
- Demonstrated adherence to visits and instructions.
Exclusion Criteria
- Severe hypoglycemic during the last month
- Severe cardiac, pulmonary or cerebral disease
- Demonstrated non compliance with clinical recommendations
- Pregnancy, nursing or women who could potentially become pregnant
- Presence of physical, psychological or cognitive impairments that would interfere with adherence to an intensive insulin therapy program or compliance with dietary, diary keeping or maintenance of CGM sensor or pump
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Insulin Treatment
There is only one arm for this study using lispro insulin administered by insulin pump.
|
To determine basal changes subject will wear a CGMS with an insulin pump infusing rapid acting insulin
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
What are the mean number of changes in the basal infusion rate(change is defined as any alternation in the basal rate >0.1 U/hr) and what are the mean differences and mean duration (hrs) of these changes.
Time Frame: week six of study
|
week six of study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
What mathematical formulas describe the relationship between the dosing factors and do they significantly differ from those previously established by King and Armstrong
Time Frame: week 6 of study
|
week 6 of study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Allen B King, MD, Diabetes Care Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2009
Primary Completion (Actual)
December 1, 2011
Study Completion (Actual)
December 1, 2011
Study Registration Dates
First Submitted
April 1, 2009
First Submitted That Met QC Criteria
April 2, 2009
First Posted (Estimate)
April 3, 2009
Study Record Updates
Last Update Posted (Estimate)
August 27, 2013
Last Update Submitted That Met QC Criteria
August 23, 2013
Last Verified
August 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1799
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
Clinical Trials on CGMS with an insulin pump using rapid acting insulin
-
Nemours Children's ClinicCompletedDiabetes Mellitus, Insulin-DependentUnited States
-
University of CambridgeMedical University of Graz; University Hospital Inselspital, Berne; Manchester...CompletedType 1 DiabetesUnited Kingdom, Austria, Switzerland
-
Mannkind CorporationJaeb Center for Health ResearchActive, not recruitingDiabetes Mellitus, Type 1United States
-
Emory UniversityCompletedDiabetes Mellitus | Type 1 DiabetesUnited States
-
Ain Shams UniversityCompletedDiabetes | Prediabetes | B-Thalassemia
-
McGill UniversityCompletedDiabetes Mellitus, Type 1 | Diabete MellitusCanada
-
Ain Shams UniversityCompletedIntraoperative ComplicationsEgypt
-
University Hospital, Strasbourg, FranceTerminatedOxidative Stress | Gestational Diabetes | Treatment | MetforminFrance
-
Northumbria UniversityDiabetes UKCompleted
-
Johns Hopkins Bloomberg School of Public HealthNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetic GastroparesisUnited States